Skip to main content

Daniel Manvich, Ph.D.

Assistant Professor

Science Center 204A
856-566-6424 
manvich@rowan.edu

Education

Emory University, Atlanta, GA
Ph.D. (Neuroscience) 2011

 

 

Research Interests

A prominent feature of cocaine abuse and dependence disorders is the frequent occurrence of relapse episodes often triggered by psychological distress and/or negative emotional affect. Stress-triggered relapse to drug use has been modeled in experimental animals for several decades using the “reinstatement procedure”, but the stressors typically used to engender drug-seeking behavior are physical or pharmacological in nature, whereas psychosocial stressors are more commonly reported to induce craving and provoke relapse in humans. This is of great concern because numerous studies have indicated that the brain circuitry mediating responses to psychosocial stress may be different from those that mediate responses to other forms of stress. To address this gap, my laboratory is currently employing a novel rodent model of psychosocial stress-induced drug seeking in combination with immunohistochemical and chemogenetic approaches to characterize which brain regions/circuits selectively mediate this unique modality of relapse-like behavior. The results of these studies could have a profound impact on our understanding of the interaction between stress and addiction processes in the brain, with the ultimate goals of 1) identifying novel biobehavioral markers for relapse vulnerability, and 2) developing novel behavioral and/or pharmacotherapeutic treatment strategies for the prevention of stress-induced drug relapse.

Recent Publications

(Updated July 2019)

  1. Manvich DF, Petko AK, Branco RC, Foster SL, Porter-Stransky KA, Stout KA, Newman AH, Miller GW, Paladini CA, Weinshenker D. Selective D2 and D3 receptor antagonists oppositely modulate cocaine responses in mice via distinct postsynaptic mechanisms in nucleus accumbens. Neuropsychopharmacology, 44(8): 1445-55, July 2019.
  2. Manvich DF, Webster KA, Foster SL, Farrell MS, Ritchie JC, Porter JH, Weinshenker D. The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice. Sci Rep, 8(1): 3840, March 2018.
  3. Di Ciano P, Manvich DF, Pushparaj A, Gappasov A, Hess EJ, Weinshenker D, Le Foll B. Effects of disulfiram on choice behavior in a rodent gambling task: association with catecholamine levels. Psychopharmacology (Berl), 235(1): 23-35, January 2018.
  4. Cubells JF, Schroeder JP, Barrie ES, Manvich DF, Sadee W, Berg T, Mercer K, Stowe TA, Liles LC, Squires KE, Mezher A, Curtin P, Perdomo DL, Szot P, Weinshenker D. Human Bacterial Artificial Chromosome (BAC) Transgenesis Fully Rescues Noradrenergic Function in Dopamine β-Hydroxylase Knockout Mice. PLoS One, 11(5): e0154864, May 2016.
  5. Manvich DF, Stowe TA, Godfrey JR, Weinshenker D. A Method for Psychosocial Stress-Induced Reinstatement of Cocaine Seeking in Rats. Biol Psychiatry, 79(11): 940-6, June 2016.
  6. Gokhale A, Vrailas-Mortimer A, Larimore J, Comstra HS, Zlatic SA, Werner E, Manvich DF, Iuvone PM, Weinshenker D, Faundez V. Neuronal copper homeostasis susceptibility by genetic defects in dysbindin, a schizophrenia susceptibility factor. Hum Mol Genet, 24(19): 5512-23, October 2015.